- Home
- XAIR vs ABP Comparison
XAIR vs ABP Comparison
Compare XAIR & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | ABP |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 12.5M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | XAIR | ABP |
|---|---|---|
| Price | $1.01 | $0.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 335.3K | ★ 2.8M |
| Earning Date | 05-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,705,000.00 | N/A |
| Revenue This Year | $126.42 | N/A |
| Revenue Next Year | $130.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 219.67 | N/A |
| 52 Week Low | $0.15 | $0.17 |
| 52 Week High | $3.78 | $7.34 |
Technical Indicators
Market Signals| Indicator | XAIR | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 25.56 |
| Support Level | $1.02 | $0.54 |
| Resistance Level | $1.16 | $0.89 |
| Average True Range (ATR) | 0.11 | 0.27 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 43.15 | 8.20 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About ABP Abpro Holdings Inc
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.